期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙利度胺联合化疗治疗急性白血病临床疗效及对血管生成调控因子的影响 被引量：13

在线阅读 下载PDF
导出
摘要 目的探讨沙利度胺联合化疗治疗急性白血病的临床疗效及对血浆血管内皮生长因子(VEGF)及碱性成纤维细胞生长因子(bFGF)水平的影响。方法将急性白血病患者38例随机分为观察组20例和对照组18例。2组均予以常规化疗方案标准剂量化疗,观察组同时口服沙利度胺100 mg/d,治疗前及治疗后8周分别采集外周血用双抗体夹心酶联免疫吸附法(ELISA)检测血浆VEGF及bFGF的水平变化及临床疗效。另设健康对照组16例。结果观察组与对照组有效率分别为85.0%(17/20)和44.4%(8/18),差异有统计学意义(P<0.05);治疗前血浆VEGF水平分别为(376.52±225.89)pg/ml、(312.49±121.62)pg/ml(P>0.05),高于健康对照组的(133.78±20.56)pg/ml(P均<0.05);治疗后分别为(206.71±33.67)pg/ml、(280.12±30.66)pg/ml(P<0.05),高于健康对照组(P均<0.05)。观察组与对照组治疗前血浆bFGF水平分别为(2.56±0.32)ng/ml、(2.43±0.30)ng/ml(P>0.05),均高于健康对照组的(1.78±0.41)ng/ml(P<0.05);治疗后分别为(2.10±0.15)ng/m1、(2.08±0.29)ng/ml(P>0.05),均高于健康对照组(P均<0.05);2组治疗后不良反应相比差异无统计学意义(P均>0.05)。结论沙利度胺联合化疗可提高急性白血病的临床缓解率,可能通过抑制血浆VEGF及其受体表达而发挥抗白血病作用。
作者 杨敬敬 李焱 杨志峰
机构地区 河北省邯郸市第一医院血液内科
出处 《疑难病杂志》 CAS 2013年第8期639-640,共2页 Chinese Journal of Difficult and Complicated Cases
关键词 白血病 急性 沙利度胺 血管内皮生长因子 碱性成纤维细胞生长因子
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor path- way intumor growth and angiogenesis [ J 1. Clin Oncol, 2005,23 (5) : 1011-1027.
  • 2张之南,沈悌.血液病诊断与疗效标准[M].3版.北京:科学出版社,2007:116-121.
  • 3吕静,刘宁,刘克为,丁爱萍,王昊,邱文生.XELOX联合沙利度胺-线治疗转移性结直肠癌的Ⅱ期随机对照研究[J].中国肿瘤临床,2011,38(16):981-984. 被引量：5
  • 4Eichholz A, Merchant S, Gaya AM. Anti-angiogenesis therapies : their po- tential in cancer management [ J ]. Onco Target Ther,2010,24 ( 3 ) :69-82.
  • 5Keyhani A,Jendiroba DR,Freiich EJ. Angiogenesis and leukemia [ J]. Leukemia[ J ]. Leuk Res ,2001,25 ( 8 ) :639-645.
  • 6Kim DH, Lee NY, Lee MH, et al. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism carl predict the prognosis in acute myeloid leukemia patients [ J ]. Br J Haematol, 2008,140 ( 1 ) :71-79.
  • 7Lee CY, Tien HF, Hu cY, et al. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukemia [ J] . Bri J Cancer,2007,97 (7) :877-882.
  • 8Koster A,van Krieken JH, Mackenzie MA, et al. Increased vasculariza- tion predicts favonble outcome in follicular lymphoma [ J ]. Clin Cancer Res,2005,11 ( 1 ) :154-161.

二级参考文献13

  • 1张弘纲,李进,秦叔逵,张燕军,宋恕平,储大同.国产伊立替康加5-氟尿嘧啶加亚叶酸钙联合沙利度胺治疗晚期大肠癌的随机对照研究[J].中华肿瘤杂志,2007,29(3):228-231. 被引量：16
  • 2Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastat- ic colorectal cancer[J].J Clin Oncol, 2004, 22(11): 2084-2091.
  • 3Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma[J].J Clin Oncol,2010, 28(12):2077-2084.
  • 4Noman AS, Koide N, Hassan F, et al. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulafon of MyD88 expression[J]. Innate Immun, 2009, 15(1): 33-41.
  • 5Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer[J].J Clin Oncol, 2008, 26(12): 2006-2012.
  • 6Conroy T, Hebbar M, BennounaJ, et al. Quality-of-life findings from a randomised phase-Ⅲ study of XELOX vs FOLFOX-6 in metastatic colorectal cancer[J]. BrJ Cancer, 2010, 102(1): 59-67.
  • 7Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials[J]. BrJ Cancer, 2009, 101(1): 12-18.
  • 8Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study[J]. J Clin Oncol, 2008, 26(12): 2013-2019.
  • 9Liu WM, HenryJY, Meyer B, et al. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodu- latory drugs (IMiDs) [J]. BrJ Cancer, 2009, 101 (5):803-812.
  • 10Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy[J]. Blood, 2000, 96(9): 2943-2950.

共引文献42

同被引文献84

引证文献13

二级引证文献59

疑难病杂志
2013年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部